PE20221588A1 - Degradador selectivo del receptor de estrogeno - Google Patents

Degradador selectivo del receptor de estrogeno

Info

Publication number
PE20221588A1
PE20221588A1 PE2022000135A PE2022000135A PE20221588A1 PE 20221588 A1 PE20221588 A1 PE 20221588A1 PE 2022000135 A PE2022000135 A PE 2022000135A PE 2022000135 A PE2022000135 A PE 2022000135A PE 20221588 A1 PE20221588 A1 PE 20221588A1
Authority
PE
Peru
Prior art keywords
estrogen receptor
selective estrogen
receptor degrader
chromen
azetidin
Prior art date
Application number
PE2022000135A
Other languages
English (en)
Inventor
Ranjan Kumar Pal
Biswajit Samanta
Jayraj Dilipbhai Aradhye
Sandeep Pankajkumar Pathak
Kaushik Dhanjibhai Prajapati
Bhavesh Mohanbhai Panchal
Trinadha Rao Chitturi
Original Assignee
Sun Pharma Advanced Res Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sun Pharma Advanced Res Co Ltd filed Critical Sun Pharma Advanced Res Co Ltd
Publication of PE20221588A1 publication Critical patent/PE20221588A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/10—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing aromatic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/397—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having four-membered rings, e.g. azetidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

Un degradador selectivo del receptor de estrogeno (SERD), un compuesto 3-(3,5-difluorofenil)-2-[4-[(E)-3-[3-(fluorometil)azetidin-1-il]prop-1-enil]fenil]-4-metil-2H-cromen-7-ol y su enantiomero S, (2S)-3-(3,5-difluorofenil)-2-[4-[(E)-3-[3-(fluorometil)azetidin-1-il]prop-1-enil]fenil]-4-metil-2H-cromen-7-ol, o sales farmaceuticamente aceptables de estos. Tambien se proporcionan procesos para su preparacion. Tambien se proporciona el uso de estos compuestos para el tratamiento de enfermedades relacionadas con la modulacion de los receptores de estrogeno, tales como el cancer de mama positivo para ER.
PE2022000135A 2019-07-22 2020-07-22 Degradador selectivo del receptor de estrogeno PE20221588A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
IN201921029554 2019-07-22
PCT/IB2020/056914 WO2021014386A1 (en) 2019-07-22 2020-07-22 Selective estrogen receptor degrader

Publications (1)

Publication Number Publication Date
PE20221588A1 true PE20221588A1 (es) 2022-10-10

Family

ID=71842730

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2022000135A PE20221588A1 (es) 2019-07-22 2020-07-22 Degradador selectivo del receptor de estrogeno

Country Status (14)

Country Link
US (2) US11014915B2 (es)
EP (1) EP4003525A1 (es)
JP (1) JP2022541938A (es)
KR (1) KR20220046586A (es)
CN (1) CN114302879A (es)
AU (1) AU2020317099A1 (es)
BR (1) BR112022001285A2 (es)
CA (1) CA3148592A1 (es)
CL (1) CL2022000156A1 (es)
IL (1) IL290036A (es)
MX (1) MX2022001013A (es)
PE (1) PE20221588A1 (es)
WO (1) WO2021014386A1 (es)
ZA (1) ZA202201157B (es)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2022541938A (ja) * 2019-07-22 2022-09-28 サン・ファーマ・アドバンスド・リサーチ・カンパニー・リミテッド 選択的エストロゲン受容体分解剤
WO2023150056A1 (en) * 2022-02-01 2023-08-10 Eli Lilly And Company Processes for the preparation of selective estrogen receptor degraders

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5395842A (en) 1988-10-31 1995-03-07 Endorecherche Inc. Anti-estrogenic compounds and compositions
EP0470310B1 (en) 1990-08-09 1995-11-29 Council of Scientific and Industrial Research Novel benzopyrans and process for their production
US6060503A (en) 1991-12-02 2000-05-09 Endorecherche, Inc. Benzopyran-containing compounds and method for their use
US5407947A (en) 1993-11-05 1995-04-18 Eli Lilly And Company Methods for inhibiting bone loss using pyrolidine and piperidine substituted benzopyrans
US5389646A (en) 1993-12-30 1995-02-14 Zymogenetics, Inc. Methods for treatment and prevention of bone loss using 2,3-benzopyrans
AU8102398A (en) 1997-07-09 1999-02-08 Central Drug Research Institute (dl)-2,3-diaryl-2h-1-benzopyrans
DE10013782A1 (de) 2000-03-15 2001-10-18 Schering Ag 4-Fluoralkyl-2H-benzopyrane mit antiestrogener Wirksamkeit, Verfahren zu ihrer Herstellung, pharmazeutische Präparate, die diese enthalten sowie deren Verwendung zur Herstellung von Arzneimitteln
HUE033581T2 (hu) 2010-06-10 2017-12-28 Seragon Pharmaceuticals Inc Ösztrogén receptor modulátorok és alkalmazásaik
CA2857057A1 (en) 2011-12-14 2013-06-20 Seragon Pharmaceuticals, Inc. Fluorinated estrogen receptor modulators and uses thereof
CA2857061A1 (en) 2011-12-16 2013-06-20 Olema Pharmaceuticals, Inc. Novel benzopyran compounds, compositions and uses thereof
CA2915534A1 (en) 2013-06-19 2014-12-24 Seragon Pharmaceuticals, Inc. Azetidine estrogen receptor modulators and uses thereof
SG11201509508YA (en) 2013-06-19 2015-12-30 Seragon Pharmaceuticals Inc Estrogen receptor modulator and uses thereof
WO2014203132A1 (en) 2013-06-19 2014-12-24 Olema Pharmaceuticals, Inc. Substituted benzopyran compounds, compositions and uses thereof
CN103879283B (zh) * 2014-03-10 2019-01-15 浙江吉利汽车研究院有限公司 一种电动车辆
JP2017538727A (ja) * 2014-12-18 2017-12-28 エフ・ホフマン−ラ・ロシュ・アクチェンゲゼルシャフト 癌の治療に有用な２，３−ジフェニルクロメンの誘導体
WO2016174551A1 (en) 2015-04-27 2016-11-03 Pfizer Inc. Anti-estrogenic compounds
WO2016189011A1 (en) 2015-05-26 2016-12-01 F. Hoffmann-La Roche Ag Heterocyclic estrogen receptor modulators and uses thereof
RS63217B1 (sr) * 2015-10-27 2022-06-30 Sun Pharma Advanced Res Co Ltd Novi heterociklični antiestrogeni
JP2022541938A (ja) * 2019-07-22 2022-09-28 サン・ファーマ・アドバンスド・リサーチ・カンパニー・リミテッド 選択的エストロゲン受容体分解剤

Also Published As

Publication number Publication date
EP4003525A1 (en) 2022-06-01
US20210024504A1 (en) 2021-01-28
KR20220046586A (ko) 2022-04-14
IL290036A (en) 2022-03-01
AU2020317099A1 (en) 2022-02-24
ZA202201157B (en) 2023-07-26
CL2022000156A1 (es) 2022-11-18
US20210261534A1 (en) 2021-08-26
US11014915B2 (en) 2021-05-25
WO2021014386A1 (en) 2021-01-28
CN114302879A (zh) 2022-04-08
MX2022001013A (es) 2022-02-22
JP2022541938A (ja) 2022-09-28
BR112022001285A2 (pt) 2022-03-22
CA3148592A1 (en) 2021-01-28

Similar Documents

Publication Publication Date Title
CL2022000156A1 (es) Degradador selectivo del receptor de estrógeno
PH12021550296A1 (en) Substituted indoles and methods of use thereof
UY38093A (es) Moduladores del regulador de conductancia transmembrana de fibrosis quística, composiciones farmacéuticas, métodos de tratamiento y proceso de preparación de los moduladores
EA201791239A8 (ru) ТЕТРАГИДРОПИРИДО[3,4-b]ИНДОЛОВЫЕ МОДУЛЯТОРЫ ЭСТРОГЕНОВЫХ РЕЦЕПТОРОВ И ИХ ПРИМЕНЕНИЕ
UY32352A (es) Régimen de dosificación para un agonista de los receptores de s1p
UY38767A (es) Compuestos para el tratamiento de enfermedades y trastornos asociados con braf
MX2017014192A (es) Composiciones y metodos de tratamiento de una enfermedad neurodegenerativa.
UY32996A (es) Antagonistas del receptor crth2 basados en indol
EA201391491A1 (ru) Производные 2-(2,4,5-замещенного анилино)пиримидина в качестве модуляторов egfr, полезных для лечения рака
UY32350A (es) Régimen de dosificación de un agonista de los receptores de s1p
CY1117745T1 (el) Ετεροκυκλικες ενωσεις και χρηση αυτων ως ρυθμιστες υποδοχεα τυπου iii κινασων τυροσινης
UY33118A (es) Indazoles aminotiazolona sustituidos como moduladores del receptor a relacionado con estrógenos
ZA202100593B (en) Heteroaryl-substituted sulfonamide compounds and their use as therapeutic agents
WO2020081410A3 (en) Radioligands for imaging the lpa1 receptor
MX2023000787A (es) Compuestos de indol como moduladores de los receptores de andrógeno.
TN2019000175A1 (en) Benzenesulfonamide compounds and their use as therapeutic agents
CR11098A (es) Compuestos de pirido [2,3-d] pirimidina-7-ona como inhibidores de p13k-alfa para el tratamiento del cancer
PE20160050A1 (es) Inhibidores/ antiandrogenos novedosos de cyp17
AU2017268006A8 (en) Benzenesulfonamide compounds and their use as therapeutic agents
JOP20190183A1 (ar) معدِلات مستقبلات الاستروجين
SA520420768B1 (ar) مركبات بنزين سلفوناميد واستخدامها كعوامل علاجية
WO2019123482A8 (en) Pharmaceutical composition for the treatment of cancer
NZ766972A (en) Compounds having s1p5 receptor agonistic activity
MX2021007687A (es) Sales novedosas de degradadores selectivos de receptores de estrogeno.
ECSP088878A (es) Proceso para la preparación de indazolil ureas que inhiben receptores de vanilloides del subtipo 1 (vr1)